Kyowa Kirin has acquired 1 company, including 1 in the last 5 years.
Kyowa Kirin’s largest acquisition to date was in 2023, when it acquired Orchard Therapeutics for $478M. The Company’s most targeted sectors include life science (100%).
Otemachi Financial City Grand Cube, 1-9-2 Otemachi, Chiyoda-ku,
Tokyo,
43537
Japan,
www.kyowakirin.com
| Date | Target |
Value
$mlns |
Transaction Type | Acquirer | Seller |
SRC
Link |
||
|---|---|---|---|---|---|---|---|---|
| 2023-10-05 |
Orchard Therapeutics · Life Science
London, United Kingdom · www.orchard-tx.com Orchard Therapeutics is a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. Orchard Therapeutics was founded in 2015 and is based in London, United Kingdom.
|
478
68.2x REVENUE |
Add-on Acquisition |
Kyowa Kirin
|
- |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
